Genmab — Februar 2024
-
Ja, der er en del problemer med bragesnak
-
med flere og flere kursmål under fair value, er der flere og flere, der ikke tror på det
-
Det var da noget af en mavepuster
https://www.proinvestor.com/investornyt/1123299/genmab-far-skaret-kursmal-med-18-pct-af-fransk-finanshus -
-
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY
) for Difficult-to https://www.proinvestor.com/investornyt/1123507/us-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-epcoritamab-epkinly-for-difficult-to
......Men vi kan vel godt blive enige om at markedet vil se beviser først?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind